HAEMATOLOGICAL AND CUTANEOUS ADVERSE EVENTS ASSOCIATED WITH CHRONIC HEPATITIS C TREATMENT

V. Granja Berná¹, C. Sanchez Gil¹, V. Collados Arroyo¹, M.J. Aguilella Vizcaíno¹, FJ Bécares Martinez²
¹Hospital Universitario Infanta Elena, Pharmacy department, Valdemoro (Madrid), Spain.
²Hospital Universitario Fundación Jimenez Díaz, Pharmacy department, Madrid, Spain
virginia.granja@idcsalud.es

BACKGROUND:

In the last few years, new drugs (Boceprevir and Telaprevir) have been approved for treatment of Chronic Hepatitis C (HCV) Genotype 1 infection.

Triple Therapy (TT) (Boceprevir or Telaprevir + peginterferon + ribavirin) has proven to be more effective than dual therapy (peginterferon+ribavirin), but TT is associated with high rate of adverse events (AE), mainly cutaneous and haematological events, which can affect adherence to treatment.

PURPOSE:

To study the frequency of cutaneous and haematological AE in patients with HCV treatment in our hospital.

METHOD:

Retrospective observational study in which authors collected cutaneous and haematological AE reported by all HCV treated patients between January 2013 and April 2014. The CTCAE V 4.0 scale was used to evaluate the severity of AE.

RESULT:

30 patients received HCV treatment, 18 men and 12 women. The average age was 46.5 ± 8.4 years. 13 (43.3%) were treated with TT: 6 with telaprevir and 7 with boceprevir.

No patient required transfusion or erythropoietin treatment. Only one patient required peginterferon dose reduction to 135 mcg because he had a platelet count < 50,000/µL.

21 patients (70%) had skin reactions, of which 10 (47.6%) were treated with TT. Skin reactions became Grade 2 in 6 patients with TT in comparison with 2 patients with dual therapy.

CONCLUSIONS:

> The frequency of observed cutaneous and haematological AE in our study fits our expectations concerning to the published studies.
> Considering the higher cost of these treatments and the higher risk of non-adherence due to their AE, pharmacotherapy follow-up on these patients is essential.

No conflict of interest